Stockscreener 앱 받기
24.00
1.48%
0.35
시간 외 거래:
24.00
전일 마감가:
$23.65
열려 있는:
$23.65
하루 거래량:
1.30M
Relative Volume:
1.00
시가총액:
$2.12B
수익:
$172.60M
순이익/손실:
$-285.42M
주가수익비율:
-7.2809
EPS:
-3.2963
순현금흐름:
$-323.17M
1주 성능:
+0.04%
1개월 성능:
+16.34%
6개월 성능:
+62.38%
1년 성능:
+82.93%
1일 변동 폭
$23.32
$24.18
1주일 범위
$23.00
$24.43
52주 변동 폭
$8.58
$25.16
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
명칭
Syndax Pharmaceuticals Inc
전화
781-419-1400
주소
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
24.00 | 2.09B | 172.60M | -285.42M | -323.17M | -3.2963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-16 | 재개 | H.C. Wainwright | Buy |
| 2025-09-10 | 재개 | Stifel | Buy |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-08-05 | 재확인 | BTIG Research | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-06-28 | 개시 | Jefferies | Buy |
| 2024-01-31 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-10-25 | 개시 | BofA Securities | Buy |
| 2023-10-11 | 개시 | Goldman | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-11 | 개시 | Guggenheim | Buy |
| 2023-04-17 | 재개 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2023-01-03 | 개시 | JP Morgan | Overweight |
| 2022-07-28 | 재개 | B. Riley Securities | Buy |
| 2022-04-11 | 개시 | H.C. Wainwright | Buy |
| 2022-02-15 | 개시 | Goldman | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-25 | 개시 | Citigroup | Buy |
| 2021-02-18 | 개시 | B. Riley Securities | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-05-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-01-04 | 개시 | Robert W. Baird | Outperform |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | 개시 | FBR & Co. | Outperform |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2016-10-07 | 개시 | Guggenheim | Buy |
| 2016-03-28 | 개시 | Citigroup | Buy |
| 2016-03-28 | 개시 | JMP Securities | Mkt Outperform |
| 2016-03-28 | 개시 | Morgan Stanley | Overweight |
모두보기
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
Syndax Pharma: Two Drug Launches Fuel Transformational Growth (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals Q4 2025 earnings preview - MSN
Is It Time To Reassess Syndax Pharmaceuticals (SNDX) After Its 88.5% One Year Surge? - Yahoo Finance
Kingdon Capital Management L.L.C. Purchases 400,000 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Granahan Investment Management LLC Has $6.10 Million Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Boothbay Fund Management LLC - MarketBeat
Apis Capital Advisors LLC Takes Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Algert Global LLC Cuts Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Assessing Whether Syndax Pharmaceuticals (SNDX) Still Looks Undervalued After Its Recent Strong Run - simplywall.st
Syndax Pharmaceuticals, Inc. $SNDX Position Reduced by Prosight Management LP - MarketBeat
Is Syndax Pharmaceuticals (SNDX) Pricing Reflect Its 81.5% One Year Share Price Gain - simplywall.st
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment - The Motley Fool
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment - The Motley Fool
SNDX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Syndax Pharmaceuticals at Barclays Conference: Strategic Growth Focus - Investing.com
SNDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Avoiding Lag: Real-Time Signals in (SNDX) Movement - Stock Traders Daily
Syndax to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on February 26, 2026 - The Globe and Mail
Syndax Pharmaceuticals stock hits 52-week high at $22.91 By Investing.com - Investing.com Canada
JPMorgan Chase & Co. Increases Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $45.00 - MarketBeat
SNDX: JP Morgan Raises Price Target to $45Maintains Overweigh - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 1-Year HighStill a Buy? - MarketBeat
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates - MSN
Wall Street Zen Upgrades Syndax Pharmaceuticals (NASDAQ:SNDX) to Hold - MarketBeat
JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains “Overweight” Rating - MSN
Syndax Pharmaceuticals’ Earnings Call Highlights Growth Push - TipRanks
Can Syndax Pharmaceuticals Inc. stock maintain growth trajectory2026 Momentum Check & AI Forecasted Stock Moves - Naître et grandir
Syndax Pharmaceuticals, Inc. $SNDX is Knott David M Jr's 7th Largest Position - MarketBeat
Vanguard Group Inc. Buys 104,683 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Market Wrap: Is Syndax Pharmaceuticals Inc. forming a double bottomWeekly Trading Summary & Reliable Entry Point Alerts - baoquankhu1.vn
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Bitget
Syndax Pharmaceuticals reports inducement grants under Nasdaq listing rule 5635(c)(4) - marketscreener.com
Syndax Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:SNDX) 2026-03-03 - Seeking Alpha
Is Syndax Pharmaceuticals (SNDX) Pricing Reflect Pipeline Progress Or Stretching Recent Share Gains - simplywall.st
SNDX Receives Buy Rating as Citigroup Raises Price Target to $57 - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $57.00 Price Target at Citigroup - MarketBeat
Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs - Bitget
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2025 Earnings Call Transcript - Insider Monkey
Syndax Pharmaceuticals Q4 Revenue Ramp To US$68.7 Million Tests Bullish Growth Narrative - simplywall.st
Barclays Sticks to Their Buy Rating for Syndax Pharmaceuticals (SNDX) - The Globe and Mail
Syndax Pharmaceuticals (NASDAQ:SNDX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Is Syndax (SNDX) Using ESOP Shares and New Drugs to Quietly Redefine Its Investment Story? - Yahoo Finance
A Look At Syndax Pharmaceuticals (SNDX) Valuation After Q4 Revenue Beat And Wider Loss - simplywall.st
Syndax (SNDX) Q4 2025 Earnings Call Transcript - Intellectia AI
Syndax Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Syndax Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Discipline and Rules-Based Execution in SNDX Response - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Syndax Pharmaceuticals (SNDX) - The Globe and Mail
Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Ins - GuruFocus
Syndax Pharmaceuticals (SNDX) Reports Strong 2025 Earnings and Growth Prospects - GuruFocus
Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Earnings Results - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):